Literature DB >> 1327593

Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis.

L Halbwachs-Mecarelli1, P Nusbaum, L H Noël, D Reumaux, S Erlinger, J P Grünfeld, P Lesavre.   

Abstract

Autoantibodies directed against polymorphonuclear neutrophils (PMN) have been observed in serum from patients with ulcerative colitis (UC), Crohn's disease (CD) and primary sclerosing cholangitis (PSC) using indirect immunofluorescence and fixed granulocyte ELISA. Our study demonstrates the presence in the serum of these patients of autoantibodies which bind to an azurophilic granule component distinct from proteinase 3, elastase and myeloperoxidase. These autoantibodies thus belong to the ANCA family, but their antigen specificity differs from the already characterized ANCA antigens. We have found that the same ANCA antigen target, named UC-antigen, was recognized by serum IgG from patients with UC, CD and PSC. It was purified by Matrex Gel Orange A dye affinity chromatography and subsequent immunoabsorption of contaminant proteinase 3 with immobilized anti-proteinase 3 MoAb. The identity between this UC antigen and cathepsin G was demonstrated by their coelution from Matrex Gel Orange A column and the parallel titration of cathepsin G-specific enzymatic activity and UC-ANCA binding, both in partially purified UC antigen and in highly pure cathepsin G. Furthermore, the use of cathepsin G ELISA confirmed that UC, CD and PSC patients' IgG did indeed bind to cathepsin G. Comparison of the results obtained with azurophilic granule- and cathepsin G-ELISA as well as inhibition of ANCA binding by anti-cathepsin G polyclonal antibodies, revealed that in some patients cathepsin G is the main azurophilic granule target of ANCA while others have other ANCA specificities. The fact that UC, CD and PSC are frequently associated with cathepsin G ANCA, while rarely occurring in other types of vasculitis, is intriguing but suggests that these diseases may have a common pathogenetic mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327593      PMCID: PMC1554558          DOI: 10.1111/j.1365-2249.1992.tb05835.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

2.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Authors:  R H Duerr; S R Targan; C J Landers; N F LaRusso; K L Lindsay; R H Wiesner; F Shanahan
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

3.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

4.  Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.

Authors:  A J Wakefield; A M Sawyerr; A P Dhillon; R M Pittilo; P M Rowles; A A Lewis; R E Pounder
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

5.  Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site.

Authors:  K Nakajima; J C Powers; B M Ashe; M Zimmerman
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

Review 6.  Granulocyte-specific antinuclear antibodies. Possible significance for the pathogenesis, clinical features and diagnosis of rheumatoid arthritis.

Authors:  A Wiik
Journal:  Allergy       Date:  1980-06       Impact factor: 13.146

Review 7.  Alterations of the immune system in ulcerative colitis and Crohn's disease.

Authors:  R P MacDermott; W F Stenson
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

8.  Granulocyte specific antinuclear antibodies in ulcerative colitis. Aid in differential diagnosis of inflammatory bowel disease.

Authors:  H Nielsen; A Wiik; J Elmgreen
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1983-02

9.  Trends in incidence rates of ulcerative colitis and Crohn's disease.

Authors:  B M Calkins; A M Lilienfeld; C F Garland; A I Mendeloff
Journal:  Dig Dis Sci       Date:  1984-10       Impact factor: 3.199

10.  Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

Authors:  R W Chapman; M Cottone; W S Selby; H A Shepherd; S Sherlock; D P Jewell
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

View more
  32 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Comparative effects of antilactoferrin antibodies and tumor necrosis factor on neutrophil adherence to matrix proteins.

Authors:  B Zweiman; C von Allmen
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

4.  Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.

Authors:  Hiromasa Takaishi; Takanori Kanai; Atsushi Nakazawa; Fumihiko Sugata; Akira Nikai; Shigeo Yoshizawa; Yasuo Hamamoto; Shinsuke Funakoshi; Tomoharu Yajima; Yasushi Iwao; Masao Takemura; Shoichi Ozaki; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-05-30       Impact factor: 7.527

5.  [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].

Authors:  A Schnabel; E Csernok; H Schultz; M Stoffel; C Herzberg; S F Carroll; W L Gross
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 6.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

Review 7.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

8.  Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC).

Authors:  J Sobajima; S Ozaki; H Uesugi; F Osakada; H Shirakawa; M Yoshida; K Nakao
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

9.  Comparative evaluation of unfixed and fixed human neutrophils for determination of antineutrophil cytoplasmic antibodies by indirect immunofluorescence.

Authors:  P Yang
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

10.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.